Thursday, July 7, 2011

Alzheimer's Blogging:

One of the hardest things I had to deal with was sundowning.  It would start maybe around 3pm and my father in law would get anxious. He would start to pace around the house more and walk in and out side and up and down the driveway more. He seemed more confused which of course grew worse as the evening wore on.

What Causes Sundowning? Is it Frustration or Chemistry?

COLUMBUS, Ohio – New research provides the best evidence to date that the late-day anxiety and agitation sometimes seen in older institutionalized adults, especially those with dementia, has a biological basis in the brain.

The findings could help explain “sundowning,” a syndrome in which older adults show high levels of anxiety, agitation, general activity and delirium in late afternoon and evening, before they would normally go to bed.

“It’s a big problem for caregivers.  Patients can get aggressive and very disruptive,” said Tracy Bedrosian, lead author of the study and a doctoral student in neuroscience at Ohio State University.

“There have been a few clinical studies documenting sundowning, but until now there hasn’t been research in animals to see what’s going on in the brain to explain this.”

The new study found that aged mice showed significantly more activity and more anxiety-like behaviors in the hours before they would normally sleep when compared to middle-aged mice – just like sundowning in humans.

In these aged mice, the researchers found changes in parts of their brain associated with attention, emotions, and arousal, all of which could be associated with the behavior seen in sundowning.

In addition, mice that were genetically engineered to have an Alzheimer’s-like disease also showed more anxiety before sleep than did other mice.

“Some people have argued that sundowning could be explained just by a buildup of frustration of older people who couldn’t communicate their needs over the course of the day, or by other factors,” said Randy Nelson, co-author of the study and professor of neuroscience and psychology at Ohio State.

“But our findings suggest there is a real phenomenon going on here that has a biological basis.”
The study will appear in the online Early Edition of the Proceedings of the National Academy of Sciences.

In the first experiment, researchers compared middle-aged adult mice (7 months old) with aged mice (29 months old) that would resemble humans in their 80s.

Results showed that the aged mice were significantly more active than middle-aged mice in the two to three hours before they would normally go to sleep.

“The middle-aged mice had a distinct pattern of activity, with three peaks of activity during their waking hours,” Bedrosian said.

“But the aged mice had a flattened rhythm in which they showed the same level of activity throughout their active period.”

That means that in the evening, when the middle aged mice would slow down compared to their peak activity levels, the aged mice kept going.

The mice were also tested for anxiety-like behaviors at two different times during their waking hours.  The mice were placed in a maze where they were allowed to explore open areas – which are more anxiety-producing – or hide in enclosed areas.

The middle-aged mice showed consistent levels of anxiety at both times of the day.  However, the aged mice showed more anxiety when tested soon before they would have gone to sleep, which is consistent with sundowning, Bedrosian said.

There were also differences in the brains of the aged mice when compared to the middle aged mice.  The researchers looked specifically at the cholinergic system, because loss of function in that system is associated with dementia and many of the circadian changes associated with ageing.

Findings in aged mice showed greater expression of a certain enzyme – acetylcholinesterase – before sleep than earlier in the day.  High levels of this enzyme are associated with anxiety and agitation.

However, in the middle-aged mice, there were no time-of-day differences in the expression of this enzyme.

Nelson noted that drugs used to control levels of acetylcholinesterase are sometimes used on dementia patients, although there has been no research evidence that it actually had an effect on sundowning.

“These drugs were prescribed for other purposes, but it also seemed to calm patients down.  Now we have some evidence on why it works,” Nelson said.

The researchers also found differences in expression of two other proteins in the brains of the aged mice that are also associated with behavioral disturbances.

“All of these results converge to suggest there are changes in the cholinergic systems of aged mice that may be contributing to the anxiety and agitation symptoms that we documented,” Bedrosian said.

In another experiment, the researchers used mice that were genetically engineered to develop Alzheimer’s-like disease in their brain.  They were compared, at nine months of age, to similar wild-type mice of the same age.

The Alzheimer’s-like mice showed more anxiety-type behaviors when tested before they would normally sleep than they did when tested earlier in their waking period.  That is consistent with sundowning in humans, the researchers said.

However, the wild-type mice showed no differences in anxiety levels based on the time of day they were tested.

Nelson said one of the theories about sundowning is that it is tied to disruptions that often occur in the biological clocks of older people, where their sleep-wake cycles are fragmented.

To test this theory, the researchers also treated the aged mice with melatonin for four weeks in order to help consolidate their circadian rhythms.  However, this treatment did not work to reduce anxiety issues in the mice.

Nelson said melatonin alone may not work because it doesn’t deal with the disruptions in the cholinergic system that was identified in this study.

“We need to study whether treating cholinergic dysfunction alone or in combination with melatonin treatment will help deal with sundowning symptoms,” he said.

I found this on Alzheimers Weekly; http://alzheimersweekly.com/content/what-causes-sundowning-frustration-chemistry

I hope this helps.
Sincerely,
Marie Fostino
Alzheimer's A Caretakers Journal
Seaboard Press An Imprint of James A Rock Pub., Co.
http://www.mariefostino.com/
http://www.mariefostino.blogspot.com/

Wednesday, June 29, 2011

Alzheimer's Blogging:

There is life after dementia.  I have to share this with you. I just had a patient on my ambulance that is 91 yrs old.  He has been married to his  wife for 8 yrs. Yes this is his second marriage. We found his wife sitting on a chair crying. He seemed to be feeling alright, but was frightened for his wife. As we transferred him to our gurney, he kept calling out to his wife, telling her that he loves her. Whether we are famous like Glen Campbell or just a person with a normal life there is life after dementia. I guess I needed to put some positive note on this subject today.  Let me share with you this poem.

The longer I live, the more I realized the impact of attitude on life. Attitude, to me, is more important than facts. It is more important than the past, than education, than money, than circumstances, than failures, than successes, than what other people think or say or do. It is more important than appearance, giftedness or skill. It will make or  break a company...a church...a home.  The remarkable thing is that we have a choice every day regarding the attitude we will embrace for that day.  We cannot change our past...we cannot change the fact that people will act in a certain way. We cannot change the inevitable. The only thing we can do is play on the one string we have and that is our attitude...I AM CONVINCED THAT LIFE IS 10% WHAT HAPPENS TO ME AND 90% HOW I REACT TO IT.
 
Sincerely,
Marie Fostino
Alzheimer's A Caretakers Journal
Seaboard Press An Imprint of James A Rock Pub., Co.
ALZHEIMER'S BLOGGING:

GLEN CAMPBELL CONFRONTS ALZHEIMER'S AND SINGS ON:
Glen Campbell is not putting down that guitar just yet. Six months after finding he has Alzheimer's at 75, he announced his diagnosis and a new tour.

http://www.youtube.com/watch?v=RHF5Bx6cOtc&feature=player_embedded

PLEASE WATCH THIS YOUTUBE VIDEO

Sincerely,
Marie Fostino
Alzheimer's A Caretakers Journal
Seaboard Press An Imprint Of James A Rock Pub., Co.
http://www.mariefostino.com/
http://www.mariefostino.blogspot.com/

Tuesday, June 28, 2011

Alzheimer's Blog:

This piece does not have to do with Alzheimer's but it does have to do with family and tough love decisions.  Check out this article about this family and their five year old daughter with the fight of her life with Cancer. Yes I will tell you the Cancer won, and this family is going through a tough time with decisions made and end of life of their daughter. Please pray for comfort for this family. Read this article and you will be crying just like I did as I read this. Remember life is precious.

http://www.azcentral.com/12news/news/articles/2011/06/26/20110626sophie0626.html

Be an angle, practice random acts of kindness:

Sincerely,
Marie Fostino
Seaboard Press An Imprint of James A Rock Pub., Co.
http://www.mariefostino.com/
http://www.mariefostino.blogspot.com/

Wednesday, June 22, 2011

Alzheizmer's Blogging:

Glen Campbell diagnosed with Alzheimer's

NEW YORK -- Country music legend Glen Campbell has been diagnosed with Alzheimer's disease, and plans to put out his final album this summer.

Campbell's representative Bobbie Gale made the announcement Wednesday. The disease is in its early stages.

The 75-year-old's wife Kim also talked to People magazine and said they wanted to go public with his illness because they wanted fans to know if he has trouble onstage.

Campbell's CD "Ghost on the Canvas" is scheduled for release Aug. 30. He also is to go on "The Glen Campbell Goodbye Tour."

The Country Music Hall of Famer had pop and country hits with "Gentle on My Mind," ''By the Time I Get to Phoenix," and perhaps his most famous song, "Rhinestone Cowboy." He also had his own TV show on CBS.



Read more: http://www.azcentral.com/ent/celeb/articles/2011/06/22/20110622glen-campbell-diagnosed-alzheimers.html#ixzz1Q4R5pXav

Sincerely,
Marie Fostino
Alzheimer's A Caretakers Journal
Seaboard Press An Imprint Of James A Rock Pub., Co.
http://www.mariefostino.com/ 
http://www.mariefostino.blogspot.com/ 

Monday, June 20, 2011

Alzheimer's Blogging:

Have you read Alzheimer's Weekly yet this week?  There is an interesting treatment article called risperdal recall.  I have copy and pasted it for you to read. This was the drug of choice for my father in law while he was still alive.

TITUSVILLE, N.J.,  /PRNewswire/ -- Ortho-McNeil-Janssen Pharmaceuticals, Inc. is initiating a voluntary recall of one lot of RISPERDAL® (risperidone) 3mg Tablets, marketed by Janssen Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. and one lot of risperidone 2mg Tablets, marketed by Patriot Pharmaceuticals, LLC, a wholly owned subsidiary of Ortho-McNeil-Janssen Pharmaceuticals, Inc.  The recalls stem from two consumer reports of an uncharacteristic odor thought to be caused by trace amounts of TBA (2,4,6 tribromoanisole).  
TBA is a byproduct of a chemical preservative sometimes applied to wood often used in the construction of pallets on which materials are transported and stored.  In January 2010, the company instituted a number of actions to reduce the potential of TBA contamination, including requiring suppliers to certify that they do not use pallets made from chemically-treated wood.
While not considered to be toxic, TBA can generate an offensive odor and a very small number of patients have reported temporary gastrointestinal symptoms when taking other products with this odor.  As it relates to RISPERDAL® and risperidone, there have been no reported serious adverse events caused by the presence of TBA.
The RISPERDAL® lot – which includes approximately 16,000 bottles – was shipped between 8/27/2010 and 2/15/2011.  The company believes there are approximately 1,600 bottles of RISPERDAL® from this lot remaining in the marketplace.  The risperidone lot – which includes approximately 24,000 bottles – was shipped between 11/10/2010 and 1/01/2011.  The company believes there are fewer than 1,200 bottles of risperidone from this lot remaining in the marketplace.
Package Description
NDC Code
Lot Number
Expiry
 
RISPERDAL® (risperidone)
Tablets 3mg Bottles of 60 Tablets
50458-330-06
0GG904
May 2012
 
Risperidone Tablets
2mg Bottles of 60 Tablets
50458-593-60
OlG175
August 2012
 
    
RISPERDAL® (risperidone) is used for the treatment of schizophrenia in adults and adolescents ages 13-17 years.
RISPERDAL® (risperidone) is used alone or in combination with other medicines (valproate or lithium) in adults for the short-term treatment of bipolar mania; or alone in adults, children and adolescents ages 10-17 years for the short-term treatment of bipolar mania.
RISPERDAL® (risperidone) is used for the treatment of irritability associated with autistic disorder in children and adolescents ages 5-16 years.
Ortho-McNeil-Janssen Pharmaceuticals, Inc. has initiated these recalls in the U.S. and Puerto Rico at the wholesale and retail (pharmacy) level and is communicating this information to these customers.  The company does not anticipate a product shortage resulting from this action.
Patients should not stop taking their medication.  Anyone experiencing an uncharacteristic odor associated with RISPERDAL® 3mg Tablets or risperidone 2mg Tablets should return the tablets to their pharmacist, and contact their healthcare professional if they have questions.  Patients or healthcare professionals can contact the Medical Information Recall Line at 1-800-634-8977 (Monday – Friday, 9 am – 5 pm ET).  Information can also be found on http://www.risperdal.com/  and http://www.patriotpharmaceuticals.com/
Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program online, or through regular mail or by fax.
We conducted an investigation involving our suppliers to evaluate the potential source of this TBA issue. This investigation revealed that some of the wooden pallets used by one of our suppliers in its warehouse were contaminated with TBA.  In addition, some of the packaging components manufactured by our supplier were exposed to these pallets.  We have initiated a deeper investigation to determine the potential impact of these findings to other products.  We also are working with peer companies to better understand how and where TBA is entering and impacting our supply chains and what we can do to further mitigate this exposure.  
The voluntary recall, being implemented with the knowledge of the U.S. Food and Drug Administration (FDA), was initiated after enhanced surveillance and complaint monitoring programs escalated two odor-related reports.
RISPERDAL® 3mg Tablets are yellow and imprinted with "JANSSEN" on one side and R3 on the other.  Risperidone 2mg Tablets are orange and imprinted "PATR" on one side and R2 on the other. Fos

Sincerely,
Marie Fostino
Alzheimer's A Caretakers Journal
Seaboard Press An Imprint of James A Rock Pub., Co.
http://www.mariefostino.com/
http://www.mariefostino.blogspot.com/

Thursday, June 16, 2011

ALZHEIMER'S BLOGGING:

Scientists believe we are at a tipping point on Alzheimer's research. We have the ideas, the technology and the will, but we do not have a commitment from the federal government.
The Alzheimer's Breakthrough Act would advance breakthrough treatments for people living with Alzheimer's by requiring a federal commitment to Alzheimer's disease research.
If passed, the Alzheimer's Breakthrough Act would:
  • Make Alzheimer's research a priority at the National Institutes of Health (NIH) by:
    • pursuing emerging scientific and research opportunities across the 27 Institutes and Centers at NIH.
    • adopting the research recommendations from the forthcoming National Alzheimer's Plan.
  • Create public-private partnerships to develop treatments and a cure through innovative approaches to Alzheimer's research.
  • Require the leadership at NIH to provide the funding necessary to get the job done – or explain to Congress why they are not.
Over the next 40 years, caring for individuals with Alzheimer's will cost our society $20 trillion – including $15 trillion from Medicare and Medicaid. Yet from a research funding perspective, Congress has been silent on the issue of Alzheimer's. It's time to act. We must do something to conquer this devastating disease.
Thank you,
Robert Egge
VP of Public Policy
Alzheimer's Associaiton

Sincerely,
Marie Fostino
Alzheimer's A Caretakers Journal
Seaboard Press An Imprint of James A Rock Pub., Co.